SUPPLEMENTARY FIGURES

Supplementary Figure 1: Summary of study design

Supplementary Figure 2: Mean ONO-AG-367 Plasma Concentrations v. Time for AM dosing (open circle) and PM dosing (closed circle) on Day 1

Supplementary Figure 3: Mean ONO-AG-367 Plasma Concentrations v. Time for AM dosing (open circle) and PM dosing (closed circle) on Day 1
Supplementary Figure 1

Sequence 1 (QAM)  Sequence 1 (QPM)

Day -45  Day -2  Day -1  Sequence 2 (QPM)  Day 15  Day 27  Day 29  Sequence 2 (QAM)  Day 43  Day 49

<table>
<thead>
<tr>
<th>Screening</th>
<th>Predose</th>
<th>Dosing and Evaluation</th>
<th>Washout (14 days)</th>
<th>Dosing and Evaluation</th>
<th>Follow-Up</th>
</tr>
</thead>
<tbody>
<tr>
<td>(43 days)</td>
<td>(2 days)</td>
<td>(14 days dosing)</td>
<td>Predose (2 days)</td>
<td>(14 days dosing)</td>
<td></td>
</tr>
</tbody>
</table>
Supplementary Figure 2

Linear Scale

Semi-Logarithmic Scale

Plasma Concentration (pg/mL) vs. Time (h)
Supplementary Figure 3

Linear Scale

Semi-Logarithmic Scale